Journal of psychopharmacology
-
J. Psychopharmacol. (Oxford) · Jun 2018
Multicenter StudyImpact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. ⋯ Continued use of paliperidone palmitate one-month formulation/long-acting injectable antipsychotic was effective in preventing schizophrenia relapses, especially in patients with suboptimal antipsychotic adherence.